Clearmind Announces Pre-IND Meeting Date with FDA
13 mai 2022 09h30 HE
|
Clearmind Medicine Inc.
Clearmind aims to initiate clinical trials with CMND-100 by year’s end Vancouver, May 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or...
Clearmind Strengthens its Scientific Advisory Board With Substance Abuse and Mental Health Professionals
09 mai 2022 09h30 HE
|
Clearmind Medicine Inc.
Prof. Schütz’ main research interests focus on clinical interventions and health service in substance use disorders and mental health diagnoses; Prof. Weiser specializes in psychiatric disorders such...
Clearmind Medicine to Partner with Microdose for Psychedelic Capital: Mar 2022 Today, Thursday, March 24th
24 mars 2022 15h00 HE
|
Clearmind Medicine Inc.
TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the...
Clearmind Medicine Announces Positive Results on CMND-100 trials
17 mars 2022 08h00 HE
|
Clearmind Medicine Inc.
Two pre-clinical trials based on MEAI exhibited a significant suppressive effect on alcohol consumption in mice TORONTO, March 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND,...
Clearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration
08 mars 2022 08h30 HE
|
Clearmind Medicine Inc.
The companies have begun the Collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the Collaboration between the parties. TORONTO, March 08, 2022 (GLOBE...
Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event on February 3
28 janv. 2022 09h00 HE
|
Clearmind Medicine Inc.
A renowned speaker, and bestselling author, Dr. Gabor Maté is highly sought after for his expertise on a range of topics including addiction, stress and childhood development TORONTO, Jan. 28, 2022 ...
Clearmind Medicine to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20
01 oct. 2021 08h00 HE
|
Clearmind Medicine
TORONTO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and...
Mark Haden, Psychedelic Medicine Expert, Joins Clearmind Medicine’s Advisory Board
03 août 2021 07h00 HE
|
Clearmind Medicine
Toronto, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of...
Clearmind Issues Shareholder Letter
20 juil. 2021 07h00 HE
|
Clearmind Medicine
Toronto, July 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire-- Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and...